MX367796B - Usos médicos para tratar hepatitis c. - Google Patents

Usos médicos para tratar hepatitis c.

Info

Publication number
MX367796B
MX367796B MX2015003501A MX2015003501A MX367796B MX 367796 B MX367796 B MX 367796B MX 2015003501 A MX2015003501 A MX 2015003501A MX 2015003501 A MX2015003501 A MX 2015003501A MX 367796 B MX367796 B MX 367796B
Authority
MX
Mexico
Prior art keywords
methods
treating hepatitis
inhibitors
hepatitis
hcv
Prior art date
Application number
MX2015003501A
Other languages
English (en)
Other versions
MX2015003501A (es
Inventor
M Kati Warren
A Matulenko Mark
G Keddy Ryan
K Pratt John
J Maring Clarence
Wagner Rolf
Liu Dachun
Krishnan Preethi
Teresa, (Lok-Chan) Ng
J Pilot-Matias Tami
C Mistry Neeta
J Reisch Thomas
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367796(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015003501A publication Critical patent/MX2015003501A/es
Publication of MX367796B publication Critical patent/MX367796B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a inhibidores de VHC pan-genotípicos. Esta invención también se relaciona a métodos para utilizar estos inhibidores para utilizar estos inhibidores para tratar infección por VHC.
MX2015003501A 2012-09-18 2013-09-17 Usos médicos para tratar hepatitis c. MX367796B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702564P 2012-09-18 2012-09-18
PCT/US2013/060103 WO2014047039A1 (en) 2012-09-18 2013-09-17 Methods for treating hepatitis c

Publications (2)

Publication Number Publication Date
MX2015003501A MX2015003501A (es) 2015-10-26
MX367796B true MX367796B (es) 2019-09-06

Family

ID=49304326

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003501A MX367796B (es) 2012-09-18 2013-09-17 Usos médicos para tratar hepatitis c.
MX2019010600A MX2019010600A (es) 2012-09-18 2015-03-18 Usos médicos para tratar hepatitis c.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010600A MX2019010600A (es) 2012-09-18 2015-03-18 Usos médicos para tratar hepatitis c.

Country Status (25)

Country Link
US (1) US20140080868A1 (es)
EP (2) EP2897611B1 (es)
JP (4) JP6297044B2 (es)
CN (1) CN104797253A (es)
AU (2) AU2013318302B2 (es)
BR (1) BR112015006037B1 (es)
CA (1) CA2884539C (es)
CY (1) CY1122442T1 (es)
DK (1) DK2897611T3 (es)
ES (1) ES2755089T3 (es)
HK (1) HK1209319A1 (es)
HR (1) HRP20191939T1 (es)
HU (1) HUE046544T2 (es)
LT (1) LT2897611T (es)
MX (2) MX367796B (es)
NZ (1) NZ630581A (es)
PL (1) PL2897611T3 (es)
PT (1) PT2897611T (es)
RS (1) RS59640B1 (es)
RU (1) RU2665365C2 (es)
SG (2) SG11201502095SA (es)
SI (1) SI2897611T1 (es)
TW (1) TWI621436B (es)
WO (1) WO2014047039A1 (es)
ZA (1) ZA201501752B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2897611T (pt) * 2012-09-18 2019-11-27 Abbvie Inc Métodos para tratamento da hepatite c
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
AU2014239563B2 (en) * 2013-03-14 2016-05-05 Abbvie Inc. Combination of two antivirals for treating hepatitis C
CN106413711A (zh) 2014-04-02 2017-02-15 艾伯维公司 治疗hcv的方法
JP6559701B2 (ja) * 2014-04-02 2019-08-14 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための方法
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
KR102637828B1 (ko) * 2015-06-26 2024-02-20 애브비 인코포레이티드 Hcv의 치료를 위한 고형 약제학적 조성물
MX2018000240A (es) * 2015-07-08 2018-03-14 Abbvie Inc Metodos para tratar el vhc.
SG10202002900YA (en) * 2015-07-17 2020-05-28 Abbvie Inc Solid pharmaceutical compositions for treating hcv
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641859A1 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
SE1450131A1 (sv) * 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
PT2897611T (pt) * 2012-09-18 2019-11-27 Abbvie Inc Métodos para tratamento da hepatite c

Also Published As

Publication number Publication date
HRP20191939T1 (hr) 2020-01-10
TW201412311A (zh) 2014-04-01
PL2897611T3 (pl) 2020-03-31
HUE046544T2 (hu) 2020-03-30
SI2897611T1 (sl) 2019-12-31
MX2015003501A (es) 2015-10-26
MX2019010600A (es) 2020-02-03
AU2018203608A1 (en) 2018-06-14
HK1209319A1 (en) 2016-04-01
AU2013318302A1 (en) 2015-04-02
LT2897611T (lt) 2019-12-10
JP2018109035A (ja) 2018-07-12
BR112015006037B1 (pt) 2022-05-17
JP2019194241A (ja) 2019-11-07
ZA201501752B (en) 2016-08-31
ES2755089T3 (es) 2020-04-21
RU2665365C2 (ru) 2018-08-29
WO2014047039A1 (en) 2014-03-27
CA2884539C (en) 2022-06-21
EP2897611A1 (en) 2015-07-29
NZ630581A (en) 2017-02-24
CY1122442T1 (el) 2021-01-27
RU2015114543A (ru) 2016-11-10
US20140080868A1 (en) 2014-03-20
RS59640B1 (sr) 2020-01-31
CA2884539A1 (en) 2014-03-27
EP3597190A1 (en) 2020-01-22
SG10201702248UA (en) 2017-04-27
SG11201502095SA (en) 2015-05-28
AU2018203608B2 (en) 2019-12-19
DK2897611T3 (da) 2019-11-04
JP2015528511A (ja) 2015-09-28
JP6297044B2 (ja) 2018-03-20
AU2013318302B2 (en) 2018-02-22
JP6556884B2 (ja) 2019-08-07
JP2021054849A (ja) 2021-04-08
TWI621436B (zh) 2018-04-21
EP2897611B1 (en) 2019-07-24
BR112015006037A2 (pt) 2017-07-04
CN104797253A (zh) 2015-07-22
PT2897611T (pt) 2019-11-27

Similar Documents

Publication Publication Date Title
MX2019010600A (es) Usos médicos para tratar hepatitis c.
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
MX336580B (es) Metodos para el tratamiento de vhc.
MX2016005393A (es) Metodos para tratar vhc.
SA516370684B1 (ar) مثبطات بوليمراز فيروس الالتهاب الكبدي سي
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201390190A1 (ru) Ингибиторы вируса гепатита с
AU2013318309A8 (en) Methods for treating hepatitis C
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
GB201103062D0 (en) Method
EA201270616A1 (ru) Ингибиторы вируса гепатита с
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
GEP201706757B (en) Substituted nucleosides, nucleotides and analogs thereof
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
MX2015003701A (es) Composiciones para tratamiento.
PH12016502559A1 (en) Isoindoline derivatives for use in the treatment of a viral infection
HK1208364A1 (en) Method for treating hepatitis c virus infection using quercetin- containing compositions
MX348311B (es) Inhibidores nampt.
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
IN2014DN00254A (es)
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
BR112015006058A2 (pt) métodos para tratamento de hcv

Legal Events

Date Code Title Description
FG Grant or registration